Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.

Butt, A A; Yan, P; Marks, K; Shaikh, O S; Sherman, K E

Butt, A A; Yan, P; Marks, K; Shaikh, O S; Sherman, K E.

Affiliation

Butt AA; VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Yan P; Hamad Healthcare Quality Institute, Hamad Medical Corporation, Doha, Qatar.
Marks K; Weill Cornell Medical College, New York, NY, USA.
Shaikh OS; VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Sherman KE; Weill Cornell Medical College, New York, NY, USA.

Aliment Pharmacol Ther ; 44(7): 728-37, 2016 10.

Article in En | MEDLINE | ID: mdl-27459341

Subject(s)

Antiviral Agents/administration & dosage; Hepacivirus/isolation & purification; Ribavirin/administration & dosage; Aged; Antiviral Agents/therapeutic use; Drug Therapy, Combination; Female; Genotype; Hepacivirus/genetics; Humans; Liver Cirrhosis/drug therapy; Male; Middle Aged; Ribavirin/therapeutic use; Simeprevir/administration & dosage; Sofosbuvir/administration & dosage; Veterans

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Ribavirin / Hepacivirus Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2016 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google